Praluent Manufacturer Copay Program: How to Cut Your Alirocumab Costs in 2026

What Is the Praluent Manufacturer Copay Program?

The Praluent copay program is a financial assistance offering from Regeneron and Sanofi designed to lower out-of-pocket costs for commercially insured patients prescribed alirocumab. Eligible patients can receive their medication at substantially reduced cost, often paying $0 at the pharmacy counter, depending on their insurance plan's formulary placement and the specific terms active at the time of enrollment.

Alirocumab belongs to the PCSK9 inhibitor drug class, a group of monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9, resulting in dramatic LDL cholesterol reductions. The FDA approved alirocumab in 2015 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who need additional LDL lowering beyond maximally tolerated statin therapy. Because PCSK9 inhibitors carry high list prices, manufacturer copay programs have become a primary access tool for patients and prescribers trying to keep therapy affordable.

The program typically covers the difference between a patient's insurance copay or coinsurance and the program's stated maximum benefit per prescription fill. Regeneron updates program terms periodically, so the specific dollar cap on annual benefits and per-fill maximums may shift from year to year. Patients should confirm current terms through the Regeneron patient services portal or by calling the number printed on their copay card. Specialty pharmacies dispensing Praluent can also verify active benefits at the point of sale.

One point that catches patients off guard: the copay program does not apply during the Medicare Part D coverage gap (the "donut hole"), nor does it apply to any government-funded insurance. This restriction is federal law, not a Regeneron policy decision. The OIG has consistently held that manufacturer copay assistance for federal healthcare program beneficiaries raises Anti-Kickback Statute concerns.

Who Qualifies for the Copay Card?

Eligibility requires active commercial (private) health insurance that covers at least part of the Praluent prescription cost. Patients must have a valid prescription from a licensed provider, be a U.S. resident, and not be enrolled in any federal or state-funded healthcare program for their pharmacy benefit.

The following groups are excluded from manufacturer copay programs by federal regulation:

• Medicare Part D beneficiaries (including Medicare Advantage plans with Part D)
• Medicaid recipients
• TRICARE beneficiaries
• Veterans Affairs (VA) pharmacy benefit users
• Any patient whose prescription is paid for by a federal healthcare program

Patients with commercial insurance through an employer, a marketplace plan purchased through the ACA exchange, or an individual plan purchased directly from an insurer are generally eligible. However, some commercial plans use specialty pharmacy networks that may complicate copay card processing. If your plan routes Praluent through a closed specialty pharmacy, ask that pharmacy directly whether they accept the Regeneron copay card.

There is no income threshold for the commercial copay program. A patient earning $300,000 annually with a Blue Cross PPO qualifies on the same terms as a patient earning $40,000 with marketplace coverage. This distinguishes the copay card from patient assistance programs (PAPs), which are income-based and provide free drug to uninsured or underinsured patients below certain federal poverty level thresholds.

How Much Does Praluent Cost Without the Copay Program?

Without insurance or copay assistance, Praluent carries a cash price averaging approximately $580 per month. That figure translates to roughly $6,960 per year, a cost that places it among the more expensive chronic medications outside of specialty oncology and rare disease drugs.

The wholesale acquisition cost (WAC) for PCSK9 inhibitors dropped significantly in 2023 and 2024 after competitive pressure from inclisiran (Leqvio) and ongoing payer pushback. Regeneron and Sanofi reduced Praluent's list price by approximately 60% from its original 2015 launch price of over $14,000 per year. Even after that reduction, the monthly cost remains prohibitive for many patients paying out of pocket.

Insurance coverage varies widely by plan. The 2022 ACC/AHA guideline update on cholesterol management reinforced PCSK9 inhibitors as appropriate therapy for high-risk ASCVD patients and those with familial hypercholesterolemia who do not reach LDL goals on maximally tolerated statins plus ezetimibe. Despite guideline endorsement, many commercial insurers still require prior authorization, step therapy documentation (proving statin intolerance or inadequate response), and sometimes peer-to-peer review before approving coverage.

A 2019 analysis published in JAMA Cardiology found that prior authorization requirements for PCSK9 inhibitors resulted in rejection rates exceeding 50% on initial submission, though appeal success rates were substantially higher when prescribers provided complete documentation of statin intolerance or inadequate LDL response [1]. Dr. Robert Rosenson, Director of Cardiometabolics at Mount Sinai, noted: "The gap between guideline recommendations and real-world access to PCSK9 inhibitors remains one of the most frustrating barriers in preventive cardiology."

Step-by-Step: How to Enroll in the Praluent Copay Program

Enrollment is straightforward but requires attention to a few details. Most patients complete the process in under 10 minutes.

Step 1: Confirm your insurance type. Verify that your pharmacy benefit is commercial, not government-funded. Your insurance card should list a BIN, PCN, and group number for your pharmacy benefit. If you are unsure, call the member services number on the back of your card.

Step 2: Get a valid prescription. Your prescriber must write a prescription for Praluent (alirocumab) and submit any required prior authorization forms to your insurer. Many specialty pharmacies will initiate the PA process on your behalf once they receive the prescription.

Step 3: Activate the copay card. Visit the manufacturer's patient support website or call the dedicated phone line to request a copay card. You will need to provide basic information including your name, date of birth, insurance details, and prescriber information. The card is typically issued as a digital card with a BIN, PCN, group number, and member ID that your pharmacy can process as a secondary payer.

Step 4: Present at the pharmacy. When filling your prescription at the specialty pharmacy, provide both your primary insurance card and the copay card. The pharmacy processes your insurance first, then applies the copay card to cover remaining out-of-pocket costs up to the program's benefit limit.

Step 5: Re-enroll annually. Most manufacturer copay programs reset on a calendar-year basis. Set a reminder to re-enroll or confirm continued eligibility each January. Terms, benefit caps, and program availability can change at annual renewal.

What If Your Insurance Denies Praluent Coverage?

Insurance denial does not mean the end of the conversation. Prior authorization denials for PCSK9 inhibitors are common, but most can be overturned with proper documentation and persistence.

The prior authorization process typically requires prescribers to document that the patient has tried and failed (or is intolerant to) maximally tolerated statin therapy. The 2018 AHA/ACC Multisociety Guideline on Blood Cholesterol Management defines high-risk patients who merit PCSK9 inhibitor consideration: those with clinical ASCVD and LDL persistently above 70 mg/dL on maximally tolerated therapy, or those with LDL above 100 mg/dL without additional risk enhancers [2]. Providing this clinical documentation at the outset increases first-pass approval rates.

If your initial PA is denied, the next step is a formal appeal. Request the denial letter in writing, which must include the specific clinical rationale for the denial. Many insurers use outdated criteria or apply step therapy requirements beyond what guidelines recommend. A peer-to-peer review between your prescriber and the insurer's medical director can resolve many denials at this stage.

External review is available as a final option. Under the ACA, commercially insured patients have the right to an independent external review of denied claims. The external reviewer evaluates whether the insurer's denial aligns with current evidence and clinical guidelines. A study in Circulation: Cardiovascular Quality and Outcomes found that external reviews overturned PCSK9 inhibitor denials in approximately 70% of cases when guideline-concordant documentation was provided [3].

Your prescriber's office may have a benefits investigation team or can refer you to Regeneron's patient support services, which provide free assistance navigating prior authorizations and appeals.

Alternative Savings Programs for Alirocumab

The manufacturer copay card is one tool. Several other programs exist for patients who do not qualify for copay assistance or who remain unable to afford their share of the cost.

Regeneron Patient Assistance Program (PAP). For uninsured patients or those with documented financial hardship, Regeneron offers a separate patient assistance program that provides Praluent at no cost. Eligibility is income-based, typically requiring household income below 400% of the federal poverty level. Application requires documentation of income and insurance status.

Independent Copay Foundations. Nonprofit organizations such as the Patient Access Network (PAN) Foundation and the HealthWell Foundation periodically open funds for cardiovascular medications including PCSK9 inhibitors. These foundations can assist both commercially insured and, in some cases, Medicare patients (unlike manufacturer copay cards). Fund availability fluctuates. Check eligibility frequently, as funds open and close based on donation cycles.

Specialty pharmacy discount programs. Some specialty pharmacies negotiate pricing that undercuts standard cash-pay rates. Ask your pharmacy whether they participate in any discount or savings programs beyond the manufacturer card.

Inclisiran (Leqvio) as a covered alternative. If alirocumab remains unaffordable or uncovered, inclisiran (siRNA-based PCSK9 inhibitor given as a twice-yearly injection by a healthcare provider) may be on a different formulary tier with your insurer. The ORION-10 trial (N=1,561) demonstrated that inclisiran reduced LDL cholesterol by 52% at day 510 compared with placebo [4]. Because inclisiran is administered in-office, it may be covered under medical benefit (Part B equivalent for commercial plans) rather than pharmacy benefit, sometimes resulting in lower patient cost-sharing.

Clinical Evidence Supporting Alirocumab Access

Understanding why alirocumab access matters requires context on its clinical benefit. The drug is not a convenience medication. It is a cardiovascular risk reducer with hard-outcome trial data.

The ODYSSEY OUTCOMES trial (N=18,924) randomized patients with recent acute coronary syndrome to alirocumab 75 mg or 150 mg versus placebo, on top of maximally tolerated statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the composite primary endpoint of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization by 15% (HR 0.85; 95% CI 0.78 to 0.93; P<0.001) [5]. The absolute risk reduction was 1.6 percentage points, translating to a number needed to treat (NNT) of 63 over 2.8 years.

A prespecified analysis of ODYSSEY OUTCOMES showed even greater benefit among patients with baseline LDL above 100 mg/dL, with an absolute risk reduction of 3.4 percentage points and a corresponding NNT of 29 [5]. The Endocrine Society's 2020 clinical practice guideline on lipid management in endocrine disorders also endorsed PCSK9 inhibitors for high-risk patients failing conventional therapy [6].

Dr. Gregory Schwartz, lead investigator of ODYSSEY OUTCOMES, stated: "Alirocumab reduced major adverse cardiovascular events in a broad population of post-ACS patients, with the greatest absolute benefit in those with the highest baseline LDL cholesterol."

These outcomes data underscore why barriers to PCSK9 inhibitor access carry measurable clinical consequences. Each month a qualifying patient goes without therapy due to cost or coverage barriers represents accumulated cardiovascular risk that evidence-based treatment could mitigate.

Medicare Patients: What Are Your Options?

Federal law prohibits manufacturer copay cards for Medicare beneficiaries. This leaves Medicare Part D patients facing potentially significant out-of-pocket costs for Praluent, particularly in the coverage gap phase.

The Inflation Reduction Act (IRA) capped Medicare Part D out-of-pocket spending at $2,000 per year starting in 2025, a provision that substantially changes the math for expensive specialty drugs like PCSK9 inhibitors [7]. Before this cap, Medicare patients could face thousands of dollars in cost-sharing for Praluent during the coverage gap. With the $2,000 annual cap now in effect, the maximum out-of-pocket exposure for all Part D drugs combined is fixed, making PCSK9 inhibitor access more financially predictable for Medicare beneficiaries.

Medicare patients should also explore the Medicare Extra Help (Low-Income Subsidy) program, which reduces premiums, deductibles, and copays for Part D beneficiaries with limited income and resources. The independent copay foundations mentioned earlier (PAN Foundation, HealthWell Foundation) can provide grants to Medicare patients when their cardiovascular drug funds are open, because these are charitable organizations not subject to the Anti-Kickback Statute restrictions that apply to manufacturers.

State Pharmaceutical Assistance Programs (SPAPs) exist in some states and can supplement Medicare Part D coverage. Contact your state's department of aging or insurance commission to determine whether your state operates an SPAP that covers PCSK9 inhibitors.

Tips for Getting the Lowest Possible Price on Praluent

Cost optimization requires working multiple angles simultaneously. No single strategy guarantees the lowest price for every patient, but combining approaches maximizes the chance of affordable access.

First, ensure your prescriber submits a thorough prior authorization. Include LDL values on and off statin therapy, documentation of all statins tried (with reasons for discontinuation or dose limitation), current cardiovascular risk status, and specific guideline references supporting PCSK9 inhibitor use. Incomplete PAs are the most common reason for preventable denials.

Second, ask about formulary alternatives. Some insurers prefer evolocumab (Repatha) over alirocumab, or vice versa, based on rebate negotiations. The two PCSK9 inhibitors produce comparable LDL reductions. The FOURIER trial (N=27,564) showed evolocumab reduced the primary composite cardiovascular endpoint by 15% (HR 0.85; P<0.001), a result strikingly similar to ODYSSEY OUTCOMES [8]. If your insurer covers one but not the other, switching may be the fastest path to affordable access.

Third, check whether your plan covers Praluent under medical benefit when administered in a clinical setting versus pharmacy benefit for self-injection at home. Benefit design differences can result in meaningfully different cost-sharing amounts for the same drug.

Fourth, apply for the manufacturer copay card and any eligible foundation assistance simultaneously. These programs are not mutually exclusive (though they cannot be stacked on the same claim). Having both activated ensures backup coverage if one program's funds are exhausted or terms change.

Fifth, time your annual enrollment strategically. If your plan requires a new prior authorization each year, submit renewal paperwork 4 to 6 weeks before your current authorization expires to avoid gaps in coverage.